Proven efficacy and tolerability

See clinical trial results of Flebogamma® DIF in: Primary immunodeficiency Autoimmune Disease

Concentration matters: consider Flebogamma® DIF 5% for your high-risk patients

Flebogamma® DIF 5% may be an appropriate choice for many of your patients, including those who cannot tolerate a 10% IVIG solution In a recent trial, only 2.2% of infusions with Flebogamma® DIF (...)

Proven efficacy and tolerability

Flebogamma® DIF has been shown to be a safe and effective treatment for primary immunodeficiency and autoimmune disease.


Additional resources

Learn more about Grifols

Additional resources and support for Flebogamma® DIF Symposium about Biomarkers in immunodeficiency diseases (ESID 2020) 6214145288001 Learn more about Grifols